Reported about 1 month ago
RBC Capital has increased its price target for Gilead Sciences (GILD) to $95, up from $92, based on insights from a 2022 patient survey regarding lenacapavir. This survey, assessing perceptions of the drug among high-risk individuals on and off PrEP, indicates potential growth for Gilead despite a slight revenue miss in Q1 2025. Gilead's full-year revenue guidance remains at $28.4 billion, bolstered by strong demand in its HIV and liver disease segments.
Source: YAHOO